RxDoctor Payments Data

Maria Arango, MD

Family Medicine · Edinburg, TXNPI 1053313809

Payments from drug & device makers

$1,868in general payments, 2019–2025

Across 67 payments — averaging $27.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$436
  • AstraZeneca$341
  • Bayer$261
  • Lilly USA, LLC$187
  • Astellas Pharma US Inc$127
  • AbbVie$98
  • plus $418 from 8 others

What the payments were for

  • Food & beverage$1,76294%
  • Education$1066%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,868 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$25,560
Medicare patients
66
Services billed
382

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide81$122,271
OzempicSemaglutide77$95,954
MounjaroTirzepatide49$70,828
FarxigaDapagliflozin Propanediol57$65,443
JardianceEmpagliflozin43$57,103
LinzessLinaclotide53$51,978
JanuviaSitagliptin Phosphate29$40,019
ProliaDenosumab17$27,620
RexultiBrexpiprazole19$26,310
SynjardyEmpagliflozin/Metformin Hcl34$24,727
Xigduo XrDapaglifloz Propaned/Metformin19$22,768
MyrbetriqMirabegron20$22,566
JanumetSitagliptin Phos/Metformin Hcl23$22,408
EliquisApixaban20$19,317
Synjardy XrEmpagliflozin/Metformin Hcl14$15,862

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$187$193,099130 claims
Novo NordiskOzempic$436$95,95477 claims
AstraZenecaFarxiga$341$65,44357 claims
AbbVieLinzess$98$51,97853 claims
AmgenProlia$84$27,62017 claims
Otsuka America Pharmaceutical, Inc.Rexulti$84$26,31019 claims
Astellas Pharma US IncMyrbetriq$127$22,56620 claims
PfizerEliquis$56$19,31720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Edinburg

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →